ArticleJournal of clinical immunology2023

Rituximab Monotherapy Is Effective as First-Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in CVID Patients.

Giulio Tessarin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.